Scientists have created laboratory mice carrying large sections of human DNA to model X-linked dystonia-parkinsonism (XDP), a rare, incurable neurodegenerative disease that mainly affects men of Filipino descent. Two studies published in Cell on Thursday, November 19, used the mice to reveal that the disease may involve not only the death of neurons but also severe changes in glial cells, which support neurons and produce the insulating material myelin. The findings could help researchers investigate potential treatments.
XDP causes the death of neurons in the striatum, a brain region involved in movement. Its symptoms include slowed movement, tremors, muscle stiffness and involuntary muscle contractions. Symptoms typically appear at about age 39, and patients live for 13 to 16 years after symptoms begin. In later stages, problems with breathing and swallowing can lead to malnutrition, aspiration pneumonia and respiratory failure.
The condition has also been associated with considerable social stigma, which has contributed to depression and suicide among people with XDP and made the disease difficult to study. “Patients are in some ways shunned and hidden,” Shane Liddelow, an associate professor of translational neuroscience at the New York University Grossman School of Medicine, said.
A disease with a complex genetic cause
XDP is caused by a mutation in TAF1, a gene on the X chromosome that helps translate DNA sequences into proteins. The disease affects far more men than women because men have only one X chromosome and therefore do not have a second copy of the gene that could compensate for the mutation.
The mutation first appeared in people on Panay, an island in the Philippines. Because of a genetic phenomenon known as the founder effect, it has become more common among people of Filipino descent but has not spread in the same way among other populations. Research has estimated that there are approximately 5.7 cases per 100,000 people in the Philippines.
The mutation was caused by a “jumping gene,” a small piece of DNA capable of moving to a new position in the genome. In people with XDP, the jumping gene inserted itself into the middle of TAF1 and disrupted the gene’s function, said Jef D. Boeke, director of the Institute for Systems Genetics at the New York University Grossman School of Medicine and a lead developer of the SwAP-In technology used in the research.
This particular jumping gene is found only in primates, so ordinary mice cannot naturally reproduce the genetic event that causes XDP. To create a more realistic model, the researchers inserted the human genetic material, including the jumping gene, into mouse cells.
Rewriting the mouse genome
The researchers used a technique called “SwAP-In” to insert 78,000 “letters” of human DNA into mouse embryonic stem cells. The inserted sequence included part of the human TAF1 gene and the associated jumping gene involved in XDP.
In laboratory dishes and in live mice, the inserted DNA produced several characteristic features of the disease, including reduced levels of TAF1 protein, cell death and holes in the brain, particularly in the striatum.
The mouse form of XDP progresses much more quickly than the human disease. Symptoms appeared after about 1.5 months in the mice, while symptoms in people can take years to develop. The researchers suggested that humans may have a biological safety net that temporarily offsets the effects of the jumping gene, while mice may lack that protection.
The rapid progression could nevertheless make the model useful for testing treatments. “It’s so fast that we can experiment with therapeutics,” Boeke said. If an experimental drug works, its effects should become apparent quickly in the mice; if it does not, the disease should continue to progress rapidly.
“This is the kind of general method that can be used to create broadly humanized mice,” said Boeke, whose team developed SwAP-In to rewrite large sections of an organism’s genetic code by inserting synthetic DNA.
Glial cells emerge as an important target
In the second study, researchers examined how XDP affected different types of brain cells in the genetically modified mice. They found major changes in oligodendrocytes, a type of glial cell. Glial cells support and protect neurons, while oligodendrocytes produce myelin, a fatty insulating substance that wraps around nerve fibers and helps electrical signals travel.
Priya Prakash, a postdoctoral researcher in Liddelow’s lab, and her colleagues used a blue dye to label lipids and myelin in mouse brain tissue. “Where you would normally see this beautiful blue brain full of lipids and myelin, what you see is a white brain that essentially has no lipids at all,” Liddelow said. The loss was especially pronounced in the striatum and prefrontal cortex.
Additional experiments indicated that the mutation prevents oligodendrocytes from fully maturing. As a result, the cells produce less myelin in these regions of the brain. The researchers also found similar changes in brain tissue donated after death by people with XDP.
The researchers believe that widespread loss of myelin insulation may leave neurons more vulnerable to premature death. The findings challenge the long-standing view that XDP is primarily a disease of neurons.
“This disease has never been reported before,” Liddelow said of the newly identified role of supporting cells. “This concept has just been turned on its head” regarding the idea that the disease primarily affects neurons.
“This is a neurodegenerative disease, and symptoms may not initially appear in the neurons themselves,” Liddelow said. “I think this is, first, interesting from a biological perspective, but second, very important for how we develop treatments to help these patients.”
Image credit: ttsz via Getty Images
Possible treatment directions
Together, the studies suggest several possible approaches to treating XDP. One strategy would be to increase the activity of the TAF1 gene and raise the levels of the proteins it produces. That approach showed promise in experiments with mouse cells in the first study.
The second study identifies oligodendrocytes as another possible treatment target. Preventing the loss of myelin, or restoring myelin production, could potentially protect neurons. The researchers also suggested that myelin loss might become an early indicator of the disease and could help with diagnosis.
Much remains unknown about the biology of XDP and whether any treatment could reverse the underlying damage. However, the new mouse model gives researchers a way to study the disease more rapidly and allows other scientists to investigate its remaining mysteries.
This article is for informational purposes only and does not provide medical advice.
Source: www.livescience.com


